BioSpace News Archive

CB Scientific, Inc. is a provider of remote ECG cardiac monitoring products and services; simple wearable solutions for detecting potentially life-threatening heart arrhythmias in patients with heart-related issues, both domestically and internationally.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that the first patient has been enrolled in the international EFRONT Study, an observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.

Novocure announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.

Novocure reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth.

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock.

Pfizer Inc. and BioNTech SE announced that the U.S. government has purchased 50 million more doses of the companies’ COVID-19 vaccine.

BD announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority, part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.

Fulcrum Therapeutics, Inc. today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open.

Personalized therapy is related to the genetic makeup of a person. It helps doctors to understand how a tumor grows in a particular patient to identify effective screening, control, and treatment methods.